Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

Clinical trial NCT07724223 · RECRUITING

Trial details

NCT number: NCT07724223
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Colorectal Cancer (CRC)

Start date: 2026-01-16
Primary completion: 2028-10-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.